论文部分内容阅读
目的探讨经导管肝动脉化疗栓塞(TACE)联合经皮微波消融(PMCT)治疗肝细胞癌的临床疗效和安全性。方法将82例肝癌患者分为联合组(TACE+PMCT)45例,对照组(单纯TACE)37例,随访1～2年,对比两组治疗效果和不良反应。结果联合组肿瘤完全坏死和AFP水平下降>50%的患者均高于对照组,差异有统计学意义(P<0.05);联合组的1年、2年生存率均比对照组高,1年、2年复发率比对照组低,两组均未发生严重不良反应。结论 TACE+PMCT治疗直径>3cm的肝细胞癌疗效确切,安全可行。
Objective To investigate the clinical efficacy and safety of transcatheter hepatic arterial chemoembolization (TACE) combined with percutaneous microwave ablation (PMCT) in the treatment of hepatocellular carcinoma. Methods Eighty-two cases of hepatocellular carcinoma were divided into 45 cases (TACE+PMCT) and 37 cases of control group (TACE alone). Follow-up was performed for 1 to 2 years. The treatment effects and adverse reactions were compared between the two groups. Results Compared with the control group, the patients with complete tumor necrosis and AFP decreased >50% in the combined group were significantly higher than the control group (P<0.05). The one-year and two-year survival rates of the combined group were higher than those in the control group. The recurrence rate was lower in the 2-year group than in the control group. No serious adverse reactions occurred in both groups. Conclusion TACE+PMCT is effective and safe for hepatocellular carcinoma with a diameter of >3cm.